SCHEMBL1820377

SCHEMBL1820377

CON(OC)C(=O)C(C)(Oc1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.44
PPARA Q07869 1/20 0.44
KCNN4 O15554 1/20 0.40
KDM4E B2RXH2 4/20 0.38
POLB P06746 2/20 0.38
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 5/20 0.37
CES1 P23141 1/20 0.37
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
ALOX15 P16050 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820577 0.83 PPARG (0.46) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL1820819 0.82 PPARA (0.45) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL5691818 0.79 PPARG (0.61) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL27757832 0.76 MAPT (0.55) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL27520136 0.75 PPARG (0.47) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL1818707 0.74 PPARA (0.47) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL1818640 0.73 HDAC3 (0.58) PPARGPPARAKCNN4POLBHDAC3
SCHEMBL1819039 0.73 PPARA (0.46) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL1819564 0.73 PPARG (0.43) PPARGPPARAKCNN4KDM4EPOLB
SCHEMBL1823516 0.72 PPARA (0.45) PPARGPPARAKCNN4KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 PPARG 1416/4885PPARA 2595/4885KCNN4 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.